HEPA Company Profile and Key Details

Q: Who are the executives of HEPA?

Dr. Daniel J. Trepanier Ph.D.Senior Vice President of Drug Devel.Dr. John Z. Sullivan-BolyaiPart-Time ConsultantMr. John T. CavanChief Financial OfficerDr. Stephen A. Harrison FACP, M.D.Scientific Advisory Board Chair & Consultant Medical DirectorDr. Daren Ure Ph.D.Chief Scientific OfficerSharen PyatetskayaDirector of Investor RelationsDr. Launa J. Aspeslet Ph.D.Chief Operating OfficerDr. Todd M. Hobbs M.D.Chief Medical OfficerDr. Patrick R. Mayo Ph.D.Senior Vice President of Clinical PharmacologyDr. Stephen A. Harrison M.D.Scientific Advisory Board Chair & Consultant Medical DirectorDr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.Pres, Chief Executive Officer, Chief Scientific Officer & Director

NASDAQ : HEPA

Hepion Pharmaceuticals

$0.06

-0.002-3.51%

At Close 4:00 PM

67.73

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Hepion Pharmaceuticals, Inc. (HEPA) stock declined over -3.51%, trading at $0.06 on NASDAQ, down from the previous close of $0.06. The stock opened at $0.06, fluctuating between $0.06 and $0.06 in the recent session.

Stock Snapshot

0.055

Prev. Close

639.12K

Market Cap

0.055

Day Low

-0.06

P/E Ratio

-0.88

EPS (TTM)

-8.96

Cash Flow per Share

0.06

Open

11.62M

Number of Shares

0.055

Day High

100.13%

Free Float in %

1.6

Book Value

811

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	0.06	0.06	0.06	0.06	861
Apr 01, 2026	0.06	0.06	0.06	0.06	1.96K
Mar 31, 2026	0.06	0.06	0.06	0.06	923
Mar 30, 2026	0.05	0.06	0.05	0.06	2.19K
Mar 27, 2026	0.05	0.05	0.05	0.05	2.13K
Mar 25, 2026	0.05	0.05	0.05	0.05	11.04K
Mar 24, 2026	0.05	0.05	0.05	0.05	2.74K
Mar 23, 2026	0.09	0.09	0.05	0.05	1.68K
Mar 20, 2026	0.06	0.07	0.06	0.06	33.56K
Mar 19, 2026	0.05	0.07	0.05	0.06	122.53K
Mar 18, 2026	0.04	0.04	0.04	0.04	41
Mar 17, 2026	0.05	0.05	0.04	0.04	445
Mar 16, 2026	0.06	0.06	0.00	0.00	224
Mar 13, 2026	0.05	0.06	0.00	0.00	36.16K
Mar 12, 2026	0.06	0.06	0.06	0.06	399
Mar 11, 2026	0.06	0.06	0.05	0.05	924
Mar 10, 2026	0.05	0.06	0.04	0.05	9.81K
Mar 06, 2026	0.04	0.04	0.04	0.04	333
Mar 03, 2026	0.04	0.04	0.04	0.04	4
Mar 02, 2026	0.04	0.04	0.04	0.04	24.45K

Contact Details

Edison, NJ 08837

United States

https://www.hepionpharma.com 732 902 4000

About Company

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

The stock is currently mid-range between its 52-week high and low $0.03 and $0.75. With a market capitalization of about $639.12 thousand, Hepion Pharmaceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.61). Key stats such as the average daily volume over the past year has been around 13.42 thousand shares, volume is running light vs its 52-week average. Headquartered in Edison, NJ, Hepion Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Vincent LoPriore, the company employs approximately 22 people and listed since February 10, 2014. Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.

Technical Performance

HEPA has shown mixed momentum, gaining 66.9% over the past week and -99.97% over the past quarter, though year-to-date performance is down -99.99%. Short-term trend indicators are bullishly aligned (SMA20 -14.9%, SMA50 -74.64%, SMA200 -99.66%). The stock’s 14-day RSI is 25.65 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.9% below its high and over 54.86% above its low. Average 10-day trading volume of 3.18 thousand shares is below the 3-month average of 7.69 thousand, indicating normal recent market interest.

Valuation Metrics

Hepion Pharmaceuticals, Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.19 suggesting the stock is closer to book value. The P/FCF stands at -0.2, also below market averages.

Dividend & Fair Value

Hepion Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.19. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$11.12. The next quarter is forecast at $nan. Next year's EPS is expected at $15.20. Hepion Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended April 08, 2025, missed forecasts by -88.71%. The prior quarter beat by -62.11%. Over the last six quarters, Apple has recorded several small beats. These include 17.12% in April 01, 2024.

Shareholding & Insider Activity

Hepion Pharmaceuticals, Inc. has 10.98 million shares outstanding. The public float is 11.62 million shares, elevated short interest at 4.10% of float. This equals 448.18 thousand shares. The short ratio is 0.05 days. Institutional investors hold 0.2% of the float. Insiders own 0.0%. Foster Robert T holds 50.47 thousand shares, Cavan John T has 14.80 thousand shares and SAPIRSTEIN JAMES has 13.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Hepion Pharmaceuticals has not generated any revenue. Returns are negative, with ROA at -270.39% and ROE at -671.99%.
On valuation metrics, Hepion Pharmaceuticals trades at a P/E of -0.06, P/S of 0.00 and P/B of 0.19. The current ratio is 10.25 and quick ratio is 10.25. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -60.51.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Hepion Pharmaceuticals posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $67.13K (margin 0.00%). Operating income was - $45.26M (margin 0.0%). Net income was- $48.93M (EPS - $12.32).
The company ended the quarter with $14.79M in cash and short-term investments, a total debt of $209.02K, and net debt of - $14.58M. Total assets were $18.09M, with equity of $7.28M. Financials further reflected weakness, with operating cash flow of - $40.89M, free cash flow of - $40.90M, and capital expenditures of - $14.30K.

Price Forecast & Outlook

Our AI price prediction model suggests that Hepion Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.09%, with price expected at $0.06 by April 16, 2026, within a range of $0.04 to $0.08 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by July 01, 2026, with a range of $0.00 to $18.43. 1-Year Outlook: Projected gain of 7590.91%, with price at $4.23 by April 02, 2027, within a range of $0.00 to $552.47.

Key Takeaways

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares are down -99.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Hepion Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.00, suggesting 25354.55% upside. Our AI forecast model points to short-term strength (9.09% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (7590.91% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Hepion Pharmaceuticals, Inc. (HEPA) stock price?

Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) stock price is $0.06 in the last trading session. During the trading session, HEPA stock reached the peak price of $0.06 while $0.06 was the lowest point it dropped to. The percentage change in HEPA stock occurred in the recent session was -3.51% while the dollar amount for the price change in HEPA stock was - $0.00.

HEPA's industry and sector of operation?

The NASDAQ listed HEPA is part of Biotechnology industry that operates in the broader Healthcare sector. Hepion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of HEPA?

Dr. Daniel J. Trepanier Ph.D.
Senior Vice President of Drug Devel.
Dr. John Z. Sullivan-Bolyai
Part-Time Consultant
Mr. John T. Cavan
Chief Financial Officer
Dr. Stephen A. Harrison FACP, M.D.
Scientific Advisory Board Chair & Consultant Medical Director
Dr. Daren Ure Ph.D.
Chief Scientific Officer
Sharen Pyatetskaya
Director of Investor Relations
Dr. Launa J. Aspeslet Ph.D.
Chief Operating Officer
Dr. Todd M. Hobbs M.D.
Chief Medical Officer
Dr. Patrick R. Mayo Ph.D.
Senior Vice President of Clinical Pharmacology
Dr. Stephen A. Harrison M.D.
Scientific Advisory Board Chair & Consultant Medical Director
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
Pres, Chief Executive Officer, Chief Scientific Officer & Director

How HEPA did perform over past 52-week?

HEPA's closing price is 66.67% higher than its 52-week low of $0.03 where as its distance from 52-week high of $0.75 is -92.63%.

How many employees does HEPA have?

Number of HEPA employees currently stands at 22.

Link for HEPA official website?

Official Website of HEPA is: https://www.hepionpharma.com

How do I contact HEPA?

HEPA could be contacted at phone 732 902 4000 and can also be accessed through its website. HEPA operates from 399 Thornall Street, Edison, NJ 08837, United States.

How many shares of HEPA are traded daily?

HEPA stock volume for the day was 811 shares. The average number of HEPA shares traded daily for last 3 months was 13.42K.

What is the market cap of HEPA currently?

The market value of HEPA currently stands at $639.12K with its latest stock price at $0.06 and 11.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	22
Beta	1.94
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

HEPA Company Profile and Key Details

Hepion Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways